0001610717-24-000364.txt : 20240626
0001610717-24-000364.hdr.sgml : 20240626
20240626162621
ACCESSION NUMBER: 0001610717-24-000364
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240624
FILED AS OF DATE: 20240626
DATE AS OF CHANGE: 20240626
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kelsey Stephen Michael
CENTRAL INDEX KEY: 0001462808
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39219
FILM NUMBER: 241073747
MAIL ADDRESS:
STREET 1: C/O GERON CORPORATION
STREET 2: 230 CONSTITUTION DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revolution Medicines, Inc.
CENTRAL INDEX KEY: 0001628171
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 472029180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 SAGINAW DR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 415-766-3638
MAIL ADDRESS:
STREET 1: 700 SAGINAW DR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
form4.xml
X0508
4
2024-06-24
0001628171
Revolution Medicines, Inc.
RVMD
0001462808
Kelsey Stephen Michael
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
REDWOOD CITY
CA
94063
true
See Remarks
true
Common Stock
2024-06-24
4
M
0
200
4.09
A
269273
D
Common Stock
2024-06-24
4
S
0
200
39
D
269073
D
Common Stock
2024-06-25
4
M
0
16467
4.09
A
285540
D
Common Stock
2024-06-25
4
S
0
16467
39.057
D
269073
D
Stock Option (Right to Buy)
4.09
2024-06-24
4
M
0
200
0
D
2023-03-13
2029-03-12
Common Stock
200
106466
D
Stock Option (Right to Buy)
4.09
2024-06-25
4
M
0
16467
0
D
2023-03-13
2029-03-12
Common Stock
16467
89999
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
Includes 95,476 restricted stock units.
The transaction was executed in multiple trades in prices ranging from $39.00 to $39.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
President, Research and Development
/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
2024-06-26